Biotech

All Articles

Bicara, Zenas seek IPOs to drive late-phase properties toward market

.Bicara Therapies and also Zenas Biopharma have actually supplied new incentive to the IPO market al...

Genentech to shut cancer immunology study division

.Genentech will close its own cancer immunology research division, and also unit mind and also renow...

Kezar drops solid lump yet to confirm its own worth in stage 1 trial

.Kezar Life Sciences is dropping its dim phase 1 solid tumor medication as the biotech goes all-in o...

Acelyrin drops izokibep, lays off 3rd of team

.Even with izokibep keeping its newfound winning streak in the medical clinic, Acelyrin is actually ...

Rivus' phase 2 obesity-related cardiac arrest trial strikes endpoint

.Rivus Pharmaceuticals has actually plumped up the leads of its own fat-busting, muscle-sparing drug...

Ovid halts preclinical work, IV plan after soticlestat fail

.Ovid Therapeutics presently uncovered last month that it was actually trimming its own head count a...

Eli Lilly opens $700M nucleic acid R&ampD facility in Boston ma Seaport

.Eli Lilly has opened a $700 million R&ampD facility in the Boston ma Seaport, improving its RNA and...

Boundless Biography creates 'modest' discharges five months after $100M IPO

.Merely 5 months after safeguarding a $100 million IPO, Limitless Biography is actually currently gi...

Halda's $126M will certainly progress 'keep and also get rid of' tumor medicines

.The initial stages of oncology R&ampD may not be except intriguing brand-new techniques, and also H...

Lykos 'disappointments' not revealing research study infractions with author

.Psychopharmacology has pulled three write-ups concerning midstage professional trial records determ...